US 12,410,166 B2
Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
Zhixiang Yang, Ningxia (CN); Haikang Yang, Ningxia (CN); Jinbo Ji, Ningxia (CN); Lijuan Zhai, Ningxia (CN); Jian Sun, Ningxia (CN); Jingwen Ji, Ningxia (CN); Lili He, Ningxia (CN); Dong Tang, Ningxia (CN); Zafar Iqbal, Ningxia (CN); Yuanbai Liu, Ningxia (CN); Yangxiu Mu, Ningxia (CN); Xueqin Ma, Ningxia (CN); and Jianqiang Yu, Ningxia (CN)
Assigned to NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES, Ningxia (CN)
Appl. No. 18/040,129
Filed by NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES, Ningxia (CN)
PCT Filed Mar. 4, 2022, PCT No. PCT/CN2022/079306
§ 371(c)(1), (2) Date Jan. 31, 2023,
PCT Pub. No. WO2022/233181, PCT Pub. Date Nov. 10, 2022.
Claims priority of application No. PCT/CN2021/092095 (WO), filed on May 7, 2021.
Prior Publication US 2024/0132488 A1, Apr. 25, 2024
Int. Cl. C07D 471/04 (2006.01); A61K 31/407 (2006.01); A61K 31/437 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61K 31/497 (2006.01); A61P 31/04 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/407 (2013.01); A61K 31/437 (2013.01); A61K 31/444 (2013.01); A61K 31/4545 (2013.01); A61K 31/497 (2013.01); A61P 31/04 (2018.01)] 18 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Chemistry
wherein:
M is hydrogen or a pharmaceutically acceptable salt forming cation,
R is a radical selected from any of the following groups:
(1) C1-6 straight or branched chain alkyl or amino which is optionally substituted;
(2) C3-6 cycloalkyl or heterocycle which is optionally substituted;
(3) C5-6 membered aryl or heteroaryl which is optionally substituted;
(4) amine or substituted-amine which is optionally substituted;
or a deuterated compound of any such compound.